The coadministration of any of the factor Xa inhibitors or direct thrombin inhibitors is not recommended with cancer therapies that are strong P-glycoprotein inducers or inhibitors, as these DOACs, as a class, are a substrate for p-glycoprotein [113]. The gene discussed is F10; the disease is cancer.